The enhancement of Axin2 expression level in melittin-applied CRC cells compared to that in control-group CRC cells suggests that melittin suppresses EMT by inhibiting β-catenin signaling (Figure 8A). The gene discussed is AXIN2; the disease is colorectal carcinoma.